Mouse models for liver cancer. Issue 2 (5th February 2013)

• Record Type: Journal Article
• Authors: Bakiri, Latifa; Wagner, Erwin F.
• Other Names: Barbacid Mariano specialEditor.; Berns Anton specialEditor.
• Is Part Of: Molecular oncology. Volume 7:Issue 2(2013)
• Page Start: 206
• Page End: 223
• Publication Date: 2013-02-05
• Subjects: Liver cancer -- Mouse models -- Hepatocellular carcinoma models; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1016/j.molonc.2013.01.005
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Hepatocellular carcinoma (HCC), the most common form of primary liver cancer is the third leading cause of cancer‐related cell death in human and the fifth in women worldwide. The incidence of HCC is increasing despite progress in identifying risk factors, understanding disease etiology and developing anti‐viral strategies. Therapeutic options are limited and survival after diagnosis is poor. Therefore, better preventive, diagnostic and therapeutic tools are urgently needed, in particular given the increased contribution from systemic metabolic disease to HCC incidence worldwide. In the last three decades, technological advances have facilitated the generation of genetically engineered mouse models (GEMMs) to mimic the alterations frequently observed in human cancers or to conduct intervention studies and assess the relevance of candidate gene networks in tumor establishment, progression and maintenance. Because these studies allow molecular and cellular manipulations impossible to perform in patients, GEMMs have improved our understanding of this complex disease and represent a source of great potential for mechanism‐based therapy development. In this review, we provide an overview of the current state of HCC modeling in the mouse, highlighting successes, current challenges and future opportunities. Highlights: ► The treatment of HCC requires effective preventive, diagnostic and therapeutic tools. ► We review state‐of‐the‐art mouse models for HCC highlighting successes and challenges. ► We emphasize tumor‐host interactions and organ/systemic crosstalks. ► Cross‐species comparative studies will lead to knowledge‐based novel therapies.